Sickle Cell Disease (SCD)Egyptian SCDNCT07800247
Hemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional Registry
An observational study of Sickle Cell Disease (SCD), run by Ain Shams University at 2 sites in Egypt.
Trial summary
This is a retrospective descriptive study to create an institutional registry that will continue as a prospective follow-up non-intervention study that will be carried out at Hematology Oncology and BMT Department, Children's Hospital, Ain-Shams University, Cairo, Egypt. Read more about this study
- Who is it for?
- Ages Up to 39 years
- Conditions the study is for
- Sickle Cell Disease (SCD)
- How many people
- 400 participants
- Where
- 2 sitesEgypt
- Study dates
- 17 Mar 2024to 1 Mar 2027
- How long will I take part?
- 2 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 39 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: children, adolescents and young adults with sickle cell disease who were following at Hematology Oncology and BMT Unit, Children's Hospital, Ain Shams University from the initiation of clinic in 1975 till 01 Jan 2027.
Who may be able to join
- children, adolescents and young adults with sickle cell disease
Who cannot join
- other inherited anemia
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt2 sites, 1 recruiting
- Recruiting
Faculty of Medicine Ain Shams Research Institute- Clinical Research Center
Cairo, 11566
Fatma Ebeid, MD, FRCPCH, +201095569596, fatmaebeid@med.asu.edu.eg
- Active, not recruiting
Faculty of medicine ain shams university
Cairo
About this study
This is a retrospective descriptive study to create an institutional registry that will continue as a prospective follow-up non-intervention study that will be carried out at Hematology Oncology and BMT Department, Children's Hospital, Ain-Shams University, Cairo, Egypt.
- Conditions
- Sickle Cell Disease (SCD)
- Keywords
- Hemoglobin
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children, adolescents and young adults with sickle cell disease | We will start with those who were/are following at Hematology Oncology and BMT Unit, Children's Hospital, Ain Shams University |
What is being measured
The primary outcome is the main question the study is designed to answer.
Institutional database
To create databases and institutional registry for managing the clinical data
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start17 Mar 2024
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle Cell Disease (SCD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 400 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fatma Soliman Elsayed Ebeid, MD, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07800247
- Sponsor's protocol ID
- FMASU P08/2024
- Acronym
- Egyptian SCD
- Status last verified
- Aug 2026
- First submitted
- 30 Aug 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No